Komori
Sysmex (6869) · InitiativeRestated

Expansion of Proprietary Recombinant Protein Production Technology to Reagents for Other Diagnostic Tests

First written in FY2018-Q2. 2 of 3 entries say "Restated". Latest entry: FY2018.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018-Q2 – FY20182017: 120172018: 22018
Same theme, other companies
Practical application and expanded uses of genetically modified silkworm technologyA theme 2 companies write about · 0 as a headwind · 3 as a tailwind

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2018RestatedAnnual report

    「Conventional PT reagents used animal-derived materials, such as rabbit brain and human placenta, for tissue factor, their main component, creating challenges in securing a stable supply of raw materials. Applying recombinant proteins produced using our in-house silkworm-baculovirus expression system has made stable raw material production possible. Going forward, we will extend our in-house recombinant protein production technology to reagents for other testing items.」

    The policy of achieving stable raw material production through recombinant protein production technology and extending it to reagents for other testing items has been reiterated.
  2. FY2018-Q3RestatedAnnual report

    「Conventional PT reagents used animal-derived materials, such as rabbit brain and human placenta, for tissue factor, their main component, creating challenges in securing a stable supply of raw materials. Applying recombinant proteins produced using our in-house silkworm-baculovirus expression system has made stable raw material production possible. Going forward, we will extend our in-house recombinant protein production technology to reagents for other testing items.」

    The policy of achieving stable raw material production through recombinant protein production technology and extending it to reagents for other testing items has been reiterated.
  3. FY2018-Q2First statedAnnual report

    「This is the first domestically produced PT reagent to use recombinant protein mass-produced in silkworms. Going forward, we will extend our in-house recombinant protein production technology to reagents for other testing items.」

    The Company applied recombinant protein production technology using a silkworm-baculovirus expression system to PT reagents and stated for the first time its policy of extending the technology to reagents for other testing items.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sysmex yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expansion of Proprietary Recombinant Protein Production Technology to Reagents for Other Diagnostic Tests | SYSMEX CORPORATION (6869) | Komori